WALTHAM, Mass. & DURHAM, N.C.--(BUSINESS WIRE)--Life Edit ® Therapeutics Inc., an ElevateBio ® company focused on next-generation gene editing technologies and therapeutics, today announced the ...

Life Edit to receive upfront cash payment, research, and preclinical funding, and is eligible to receive milestone payments with tiered royalties on global net product sales CAMBRIDGE, MA and DURHAM, ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Life Edit Therapeutics Inc, a next generation gene-editing company, today announced that it has received an award from the Cystic Fibrosis Foundation to ...

I am a storyteller at heart. If you’ve read even a few of my blog posts, you can see this in the way I open my pieces. I always start with a story because people remember details better when they are ...

Novo Nordisk (NVO) has partnered with U.S.-based biotech Life Edit Therapeutics to discover and develop gene editing treatments targeted at rare and cardiometabolic diseases, the companies announced ...

DURHAM – Gene editing from a Durham-based firm that will target possible new therapeutics has led to a deal with international drug firm Novo Nordisk worth a potential $2 billion if not more. Life ...

Novo Nordisk, a health sciences manufacturer, is partnering with Durham’s Life Edit Therapeutics in a deal worth upwards of $1.92 billion. Photo courtesy Novo Nordisk A fast-growing Durham gene ...

Moderna’s ambitions in messenger RNA technology include therapies that do their editing work inside the patient. To that end, the biotech company is starting an R&D collaboration with a division of ...

Collaboration to combine Moderna's mRNA platform with Life Edit's proprietary gene editing technologies, including base editing capabilities Multi-target collaboration to advance potentially ...